Biochemical characterization of the binding of cyclic RGDyK to hepatic stellate cells

Biochemical Pharmacology

Volumn 80, Issue 1, 2010, Pages 136-143

  Huang, Xiao wei ^a   Wang, Ji Yao ^a   Li, Feng ^a   Song, Zheng Ji ^a   Xie, Cao ^b   Lu, Wei Yue ^b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

CRGDyK peptide; Hepatic stellate cell; Integrin v 3; Liver fibrosis; Targeted binding

Indexed keywords

ARGINYLGLYCYLASPARTYLTYROSYLLYSINE; BETA3 INTEGRIN; BIOLOGICAL MARKER; CD51 ANTIGEN; CYCLOPEPTIDE; FLUORESCEIN; IODINE 125; MESSENGER RNA; PENTAPEPTIDE; RADIOLIGAND; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL ACTIVATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RADIOIODINATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID PHASE SYNTHESIS; STELLATE CELL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUORESCENT DYES; HEPATIC STELLATE CELLS; INDOLES; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77952287970     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.015     Document Type: Article

References (41)

1. Beljaars L., Meijer D.K., Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002, 7:e214-e222.
2. Wu J., Nantz M.H., Zern M.A. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 2002, 7:d717-d725.
3. Guma F.C.R., Mello T.G., Mermelstein C.S., Fortuna V.A., Wofchuk S.T., Gottfried C., et al. Intermediate filaments modulation in an in vitro model of the hepatic stellate cell activation or conversion into the lipocyte phenotype. Biochem Cell Biol 2001, 79(4):409-417.
4. de Aguirres A.B., Mello P.A., Andrade C.M., Breier A.C., Margis R., Guaragna R.M., et al. Variations of ganglioside biosynthetic pathways in the phenotype conversion from myofibroblasts to lipocytes in murine hepatic stellate cell line. Mol Cell Biochem 2007, 303(September (1-2)):121-130.
5. Andrade C.M., Roesch G.C., Wink M.R., Guimarães E.L., Souza L.F., Jardim F.R., et al. Activity and expression of ecto-5′-nucleotidase/CD73 are increased during phenotype conversion of a hepatic stellate cell line. Life Sci 2008, 82(January (1-2)):21-29.
6. Burt A.D. Cellular and molecular aspects of hepatic fibrosis. J Pathol 1993, 170:105-114.
7. Ramm G.A., Britton R.S., O'Neill R., Blaner W.S., Bacon B.R. Vitamin A-poor lipocytes: a novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts. Am J Physiol 1995, 269:G532-G541.
8. Benyon R.C., Arthur M.J. Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr 1998, 27:75-85.
9. Ruoslahti E. RGD and other recognition sequences for integrins. Ann Rev Cell Dev Biol 1996, 12:697-715.
10. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2:91-100.
11. Bach-Gansmo T., Danielsson R., Saracco A., Wilczek B., Bogsrud T.V., Fangberget A., et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006, 47:1434-1439.
12. 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 2006, 66:9673-9681.
13. Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001, 42:326-336.
14. Haubner R., Kuhnast B., Mang C., Weber W.A., Kessler H., Wester H.J., et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004, 15:61-69.
15. 111In nanoparticles. Int J Cancer 2007, 120:1951-1957.
16. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat Med 1998, 4:623-626.
17. Winter P.M., Caruthers S.D., Kassner A., Harris T.D. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res 2003, 63:5838-5843.
18. Schmieder A.H., Winter P.M., Caruthers S.D., Harris T.D. Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magn Reson Med 2005, 53:621-627.
19. Ellegala D.B., Leong-Poi H., Carpenter J.E., Klibanov A.L. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3. Circulation 2003, 108:336-341.
20. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin alpha v beta 3 in brain tumor xenografts. Cancer Res 2004, 64:8009-8014.
21. Carloni V., Romanelli R.G., Pinzani M., Laffi G., Gentilini P. Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. Gastroenterology 1996, 110:1127-1136.
22. Zhou X., Murphy F.R., Gehdu N., Zhang J., Iredale J.P., Benyon R.C. Engagement of alpha v beta 3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 2004, 279:23996-24006.
23. Milliano M.T., Luxon B.A. Initial signaling of the fibronectin receptor (alpha 5 beta 1 integrin) in hepatic stellate cells is independent of tyrosine phosphorylation. J Hepatol 2003, 39:32-37.
24. Zhou X., Zhang Y., Zhang J., Zhu H., Du W., Zhang X., et al. Expression of fibronectin receptor, integrin alpha 5 beta 1 of hepatic stellate cells in rat liver fibrosis. Chin Med J (Engl) 2000, 113:272-276.
25. Levine D., Rockey D.C., Milner T.A., Breuss J.M., Fallon J.T., Schnapp L.M. Expression of the integrin alpha 8 beta 1 during pulmonary and hepatic fibrosis. Am J Pathol 2000, 156:1927-1935.
26. Haubner R., Finsinger D., Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997, 36:1374-1389.
27. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004, 31:11-19.
28. Benyon R.C., Hovell C.J., Da Gaca M., Jones E.H., Iredale J.P., Arthur M.J. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999, 30:977-986.
29. Ke A.W., Shi G.M., Zhou J., Wu F.Z., Ding Z.B., Hu M.Y., et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009, 49(February (2)):491-503.
30. Orlando R.A., Cheresh D.A. Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin αvβ3 and its ligand. J Biol Chem 1991, 266:19543-19550.
31. Iredale J.P. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2002, 327:143-147.
32. Wu J., Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000, 35(9):665-672.
33. Reeves H.L., Dack C.L., Day C.P., Burt A.D. Cells of the hepatic sinusoid: proceedings of the eighth international symposium on cells of the hepatic sinusoid, vol. 6 1997, 154-155. The Kupffer Cell Foundation, Leiden, The Netherlands. E. Wisse, D.L. Knook, C. Balabaud (Eds.).
34. Aina O.H., Marik J., Liu R., Lau D.H., Lam K.S. Identification of novel targeting peptides for human ovarian cancer cells using " one-bead one-compound" combinatorial libraries. Mol Cancer Ther 2005, 4:806-813.
35. Du S.L., Pan H., Lu W.Y., Wang J., Wu J., Wang J.Y. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007, 322:560-568.
36. Liu S. Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009 [online publication].
37. Patsenker E., Popov Y., Wiesner M., Goodman S.L., Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 2007, 46:878-887.
38. Chung A.S., Gao Q., Kao W.J. Either integrin subunit beta1 or beta3 is involved in mediating monocyte adhesion, IL-1beta protein and mRNA expression in response to surfaces functionalized with fibronectin-derived peptides. J Biomater Sci Polym Ed 2007, 18:713-729.
39. Wu L.Q., Zhang W.J., Niu J.X., Ye L.Y., Yang Z.H., Grau G.E., et al. Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J Vasc Res 2008, 45(1):78-86.
40. Edwards S., Lalor P.F., Tuncer C., Adams D.H. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an αvβ3-independent manner. Br J Cancer 2006, 95(December (11)):1545-1554.
41. Harui A., Roth M.D., Vira D., Sanghvi M., Mizuguchi H., Basak S.K. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of αvβ3 integrins. J Leukoc Biol 2006, 79(June (6)):1271-1278.